Metrochem API Private Limited Metrochem API Private Limited

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexion Pharmaceuticals Receives Study May Proceed Letter from FDA for a Phase 1b\/2 Clinical Trial of BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals for Dioleoyl Phosphatidylserine

    Menu

    Dioleoyl Phosphatidylserine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    MARKET PLACE

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Bexion Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bexion Pharmaceuticals Receives Study May Proceed Letter from FDA for a Phase 1b/2 Clinical Trial of BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

              Details:

              BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a cell membrane phospholipid used for solid tumors and gliomas.

              Lead Product(s): Saposin C,Dioleoyl Phosphatidylserine

              Therapeutic Area: Oncology Product Name: BXQ-350

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Veranova: A CDMO that manages complexity with confidence.
              Axplora- The partner of choice for complex APIs.
              Post Enquiry
              POST ENQUIRY